基于人群的乳腺癌筛查项目中双体位数字乳腺断层合成与数字乳腺X线摄影的比较(To-Be):一项随机对照试验
在挪威Bergen的乳腺癌筛查项目中,将29453名50-69岁女性随机分配至数字乳腺断层合成(含合成2D乳腺图像)组或数字乳腺X线摄影组。筛查检出乳腺癌比例两组无显著差异(0.66% vs 0.61%,RR 1.09,95%CI 0.82-1.46,p=0.56)。作者认为数字乳腺断层合成作为筛查工具与标准数字乳腺X线摄影无显著差异,需经济分析和随访研究进一步了解其效果。
要点
- 数字乳腺断层合成组筛查检出乳腺癌0.66%(95/14380),数字乳腺X线摄影组0.61%(87/14369),RR 1.09(95%CI 0.82-1.46),p=0.56,无显著差异。
- 研究纳入29453名50-69岁女性,随机分配至数字乳腺断层合成(n=14380)或数字乳腺X线摄影(n=14369)进行意向性分析。
- 作者认为数字乳腺断层合成包括合成2D乳腺图像作为筛查工具与标准数字乳腺X线摄影无显著差异。
核心结论
- 本研究表明,在基于人群的筛查项目中,数字乳腺断层合成包括合成2D乳腺图像作为乳腺癌检测筛查工具与标准数字乳腺X线摄影无显著差异。
- 需要经济分析以及关于间期癌和连续轮次筛查检出乳腺癌的随访研究,以更好地理解数字乳腺断层合成在基于人群的乳腺癌筛查中的效果。
研究设计与样本
- 随机对照试验,平行组设计,在挪威Bergen的BreastScreen Norway筛查项目中开展。
- 2016年1月14日至2017年12月31日期间邀请44266名女性,32976名(74.5%)参加。
- 排除乳房植入物女性和未同意参与者后,29453名(89.3%)符合电子随机化条件,按1:1简单随机化分配至数字乳腺断层合成组(n=14734)或数字乳腺X线摄影组(n=14719)。
- 随机化后排除既往乳腺癌患者(数字乳腺断层合成组n=314,数字乳腺X线摄影组n=316)、黑色素瘤转移患者(数字乳腺断层合成组n=1)及提供同意后告知放射技师乳房症状者(数字乳腺断层合成组n=39,数字乳腺X线摄影组n=34),最终分析纳入28749名女性(数字乳腺断层合成组n=14380,数字乳腺X线摄影组n=14369)。
- 主要结局为筛查检出的乳腺癌,按筛查技术分层,采用对数二项回归模型估计粗风险比(RR)及95%CI,采用符合方案分析。
主要发现
- 筛查检出乳腺癌比例两组无显著差异:数字乳腺断层合成组95例(0.66%,95%CI 0.53-0.79)vs 数字乳腺X线摄影组87例(0.61%,95%CI 0.48-0.73),RR 1.09(95%CI 0.82-1.46),p=0.56。
临床怎么用
- 作者认为数字乳腺断层合成包括合成2D乳腺图像作为筛查工具与标准数字乳腺X线摄影无显著差异。
- 作者提出需要经济分析以及关于间期癌和连续轮次筛查检出乳腺癌的随访研究,以更好地理解数字乳腺断层合成在基于人群的乳腺癌筛查中的效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening programme. METHODS: BreastScreen Norway offers all women aged 50-69 years two-view (craniocaudal and mediolateral oblique) mammographic screening every 2 years and does independent double reading with consensus. We asked all 32 976 women who attended the programme in Bergen in 2016-17, to participate in this randomised, controlled trial with a parallel group design. A study-specific software was developed to allocate women to either digital breast tomosynthesis or digital mammography using a 1:1 simple randomisation method based on participants' unique national identity numbers. The interviewing radiographer did the randomisation by entering the number into the software. Randomisation was done after consent and was therefore concealed from both the women and the radiographer at the time of consent; the algorithm was not disclosed to radiographers during the recruitment period. All data needed for analyses were complete 12 months after the recruitment period ended. The primary outcome measure was screen-detected breast cancer, stratified by screening technique (ie, digital breast tomosynthesis and digital mammography). A log-binomial regression model was used to estimate the efficacy of digital breast tomosynthesis versus digital mammography, defined as the crude risk ratios (RRs) with 95% CIs for screen-detected breast cancer for women screened during the recruitment period. A per-protocol approach was used in the analyses. This trial is registered at ClinicalTrials.gov, number NCT02835625, and is closed to accrual. FINDINGS: Between, Jan 14, 2016, and Dec 31, 2017, 44 266 women were invited to the screening programme in Bergen, and 32 976 (74·5%) attended. After excluding women with breast implants and women who did not consent to participate, 29 453 (89·3%) were eligible for electronic randomisation. 14 734 women were allocated to digital breast tomosynthesis and 14 719 to digital mammography. After randomisation, women with a previous breast cancer were excluded (digital breast tomosynthesis group n=314, digital mammography group n=316), women with metastases from melanoma (digital breast tomosynthesis group n=1), and women who informed the radiographer about breast symptoms after providing consent (digital breast tomosynthesis group n=39, digital mammography group n=34). After exclusions, information from 28 749 women were included in the analyses (digital breast tomosynthesis group n=14 380, digital mammography group n=14 369). The proportion of screen-detected breast cancer among the screened women did not differ between the two groups (95 [0·66%, 0·53-0·79] of 14 380 vs 87 [0·61%, 0·48-0·73] of 14 369; RR 1·09, 95% CI 0·82-1·46; p=0·56). INTERPRETATION: This study indicated that digital breast tomosynthesis including synthetic 2D mammograms was not significantly different from standard digital mammography as a screening tool for the detection of breast cancer in a population-based screening programme. Economic analyses and follow-up studies on interval and consecutive round screen-detected breast cancers are needed to better understand the effect of digital breast tomosynthesis in population-based breast cancer screening. FUNDING: Cancer Registry of Norway, Department of Radiology at Haukeland University Hospital, University of Oslo, and Research Council of Norway.
引用
- Hofvind S, Holen ÅS, Aase HS, et al. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. Lancet Oncol. 2019. PMID: 31078459. doi:10.1016/S1470-2045(19)30161-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。